arrow
T

Tatiane Vilaça

University of Sheffield
H指数:15
被引数:1,403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to Letter to the Editor regarding “The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH–ASBMR–SABRE project”

对“治疗相关变化对骨质疏松症临床 trial 中总髋部BMD在12、18和24个月测量与骨折风险降低的关系:FNIH–ASBMR–SABRE项目”一文的编者来信的回复

2026-01-190
PRE
Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study

与治疗相关的全髋骨矿物质密度变化适用于不同研究设计的试验以及作用机制不同的药物:FNIH-ASBMR SABRE研究中的meta回归结果

2025-09-010
OAAI
The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project

使用来自fnih-asbmr-sabre项目的个体患者数据的随机对照试验的安慰剂组中基线骨矿物质密度与骨折发生率之间的关系

2024-12-160
PRE
The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project

在骨质疏松症临床试验中,在12、18和24个月后测量的全髋关节BMD的治疗相关变化与骨折风险降低之间的关系: fnih-asbmr-sabre项目

2024-08-041
OAAI
Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project

治疗前骨密度和药物治疗对骨折风险和BMD变化的益处: 来自fnih-asbmr SABRE项目的分析

2024-05-017
OAAI
Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project

年龄对降低骨折风险和增加BMD的药物治疗效果的影响: fnih-asbmr-sabre项目的RCT结果

2024-03-191
OAAI
A new FRAX model for Brazil
2023-11-283
OAAI